What's New
News
Balancing Safety and Autonomy When Persons Diagnosed Leave the Home
In recent days, national media outlets have reported on the disappearance of Edmond Bradley Solomon III, a…
AFTD Partners with ALS Association to Support Advancing Digital Tools
Although FTD and amyotrophic lateral sclerosis (ALS) have long been considered distinct disorders, experts now recognize that…
AFTD CEO Discusses Wendy Williams’s FTD Diagnosis
In an interview with The Daily Beast about Wendy Williams’s recent FTD diagnosis, AFTD CEO Susan L-J…
FDA Grants Breakthrough Therapy Designation to Experimental FTD Therapy
The U.S. Food and Drug Administration (FDA) has granted a “breakthrough therapy designation” to latozinemab, an experimental…
AFTD and ADDF Extend Treat FTD Fund Program Through 2035
AFTD and the Alzheimer’s Drug Discovery Foundation (ADDF) have committed to extending the Treat FTD Fund program…
Open Hand Foundation Provides AFTD $600K for FTD Research
AFTD is pleased to announce that we have received a gift of $600,000 from the Open Hand…
Provide Help and Bring Hope with a Year-End Gift
AFTD was founded more than 20 years ago with a single donation. Since then, the dedication and…
U.S. Rep. Jennifer Wexton Announces Progressive Supranuclear Palsy Diagnosis
Representative Jennifer Wexton of Virginia announced last week that she would not be seeking re-election after receiving…
AFTD and Passage Bio Discuss Therapeutics Designed for FTD-GRN
AFTD recently spoke with Passage Bio Chief Executive Officer William Chou, M.D., about his colleagues’ work to…
AFTD and Denali Therapeutics Discuss Takeda Pharmaceuticals Partnership to Develop FTD-Focused Therapeutic
Recently, members of the Denali Therapeutics team provided insights into their work and partnership with Takeda to…
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)